Immunotherapy for drug-refractory mucosal leishmaniasis

Area of Science:

• Immunology
• Parasitology
• Tropical Medicine

Background:

• Pentavalent antimony (Sb(v)) is the primary treatment for mucosal leishmaniasis (ML), but its toxicity and high relapse rates necessitate alternative therapies.
• Current immunotherapy options, like killed parasites with or without bacille Calmette-Guerin, yield inconsistent results, limiting their widespread use.

Purpose of the Study:

• To evaluate the safety and efficacy of a novel immunotherapeutic antigen preparation in patients with drug-refractory ML.
• To assess the long-term outcomes of this defined antigen-based vaccine therapy.

Main Methods:

• An observational, open-label trial was conducted involving 6 patients with ML who failed prior Sb(v) therapy.
• Patients received a defined antigen preparation including Leishmania antigens and granulocyte-macrophage colony-stimulating factor.
• Clinical and pathological evaluations were performed at multiple time points up to 60 months post-treatment.

Main Results:

• One patient achieved complete clinical remission after the third injection and remained disease-free throughout the study.
• At 9 months, 5 patients showed complete clinical remission.
• All 6 patients were asymptomatic at the 5-year follow-up examination.

Conclusions:

• Vaccine therapy using a defined antigen combination is a safe and effective treatment for drug-refractory ML.
• This approach, when combined with standard chemotherapy, offers a promising alternative for patients with treatment failure.
• The study supports the potential of defined antigen immunotherapy for improving ML treatment outcomes.